SRD5A3-CDG: a patient with a novel mutation.

Area of Science:

• Biochemistry
• Genetics
• Molecular Biology

Background:

• Congenital disorders of glycosylation (CDG) encompass a group of genetic diseases characterized by defects in the synthesis of glycoproteins and glycolipids.
• Over 45 distinct CDG types have been identified, highlighting the complexity of protein glycosylation pathways.
• Dolichol phosphate is crucial for N-glycan assembly in the endoplasmic reticulum, making its biosynthesis a key area of CDG research.

Observation:

• This report focuses on a patient diagnosed with Steroid 5alpha-reductase type 3 deficiency (SRD5A3-CDG), a recently identified CDG type.
• The patient presented with a novel homozygous mutation within the SRD5A3 gene.
• Diagnostic features included psychomotor retardation, nystagmus, visual impairment, cerebellar abnormalities, ataxia, and ichthyosiform skin lesions.

Findings:

• The study identifies a novel homozygous mutation in the Steroid 5alpha-reductase type 3 (SRD5A3) gene, leading to SRD5A3-CDG.
• This mutation affects the final steps of dolichol phosphate biosynthesis, a critical pathway for protein glycosylation.
• The patient's clinical presentation provides further insight into the phenotypic spectrum of SRD5A3-CDG.

Implications:

• This discovery expands the known genetic variations causing CDG and deepens our understanding of SRD5A3-CDG.
• Identifying novel mutations aids in accurate diagnosis and potential therapeutic strategies for patients with CDG.
• Further research into dolichol phosphate biosynthesis defects can illuminate fundamental aspects of cellular metabolism and disease pathogenesis.